<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="231159">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00069082</url>
  </required_header>
  <id_info>
    <org_study_id>WL-1001-02-05</org_study_id>
    <nct_id>NCT00069082</nct_id>
  </id_info>
  <brief_title>Intranasal Civamide for Episodic Cluster Headache</brief_title>
  <official_title>A Phase III, Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Multicenter Evaluation of Civamide (Zucapsaicin) Nasal Solution in the Treatment of Episodic Cluster Headache</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Winston Laboratories</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Winston Laboratories</source>
  <brief_summary>
    <textblock>
      This is a 49-day study to evaluate the effectiveness of Intranasal Civamide (Zucapsaicin) in
      the treatment of an episodic cluster headache period compared to placebo (medically inactive
      substance which does not contain any active ingredients).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2003</start_date>
  <completion_date type="Actual">January 2004</completion_date>
  <primary_completion_date type="Actual">January 2004</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">2</enrollment>
  <condition>Episodic Cluster Headache</condition>
  <arm_group>
    <arm_group_label>Civamide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Nasal Solution 0.01%</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo nasal solution with sodium chloride 10%</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Civamide (Zucapsaicin)</intervention_name>
    <description>Nasal Solution 0.01%</description>
    <arm_group_label>Civamide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sodium Chloride</intervention_name>
    <description>Nasal Solution 10%</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  At least 2 year history of episodic cluster headache (meeting IHS criteria)

          -  At least 2 previous episodes

          -  Expected duration of cluster period is at least 6 weeks but not longer than 24 weeks

          -  At least 1 but not more than 8 headaches on each of the 3 days immediately prior to
             treatment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Scott B Phillips, MD</last_name>
    <role>Study Director</role>
    <affiliation>Winston Laboratories</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>San Francisco Clinical Research Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>California Medical Clinic for Headache</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Colorado Neurology and Headache Clinic</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80218</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diamond Headache Clinic</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York Headache Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Foundation</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2011</verification_date>
  <lastchanged_date>June 8, 2011</lastchanged_date>
  <firstreceived_date>September 15, 2003</firstreceived_date>
  <responsible_party>
    <name_title>Scott B. Phillips, M.D., Study Director</name_title>
    <organization>Winston Laboratories, Inc.</organization>
  </responsible_party>
  <keyword>Headache</keyword>
  <keyword>Cluster</keyword>
  <keyword>EC</keyword>
  <keyword>Episodic Cluster</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Headache</mesh_term>
    <mesh_term>Cluster Headache</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Capsaicin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
